| Dr Lucie Donikian, PHARM D | |
|
189 South St, Shrewsbury, MA 01545-5401 | |
| (508) 736-2599 | |
| Not Available |
| Full Name | Dr Lucie Donikian |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 189 South St, Shrewsbury, Massachusetts |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1164738738 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | PH233233 (Massachusetts) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Lucie Donikian, PHARM D 189 South St, Shrewsbury, MA 01545-5401 Ph: (508) 736-2599 | Dr Lucie Donikian, PHARM D 189 South St, Shrewsbury, MA 01545-5401 Ph: (508) 736-2599 |
News Archive
Watson Pharmaceuticals, Inc. today reported net income for the first quarter 2012 increased 87 percent to $208.8 million or $1.64 per diluted share on a non-GAAP basis, compared to $111.9 million or $0.89 per diluted share in the first quarter 2011.
Nearly a quarter century ago, a genetic variant known as ApoE4 was identified as a major risk factor for Alzheimer's disease- one that increases a person's chances of developing the neurodegenerative disease by up to 12 times.
In a New England Journal of Medicine "Perspective" published today, Wafaa El-Sadr, MD, MPH, global director of ICAP at Columbia University Mailman School of Public Health, and Jessica Justman, MD, ICAP's senior technical director, and associate professor of epidemiology, urge a coordinated global effort in the face of the COVID-19 pandemic, with "countries around the world [taking] concrete steps to assist Africa in staying ahead of the curve, even as they confront their own epidemics."
Arrowhead Research Corporation, a targeted therapeutics company, today announced that, through its Calando Pharmaceuticals subsidiary, it has completed enrollment of a phase 1b clinical trial of CALAA-01, its RNAi therapeutic candidate targeting solid tumors. All patients participating in the trial have completed dosing with the exception of one patient who is still receiving treatment and will continue to be monitored.
› Verified 6 days ago
Fadi Zakaria, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 225 Boston Tpke, Shrewsbury, MA 01545 Phone: 508-756-4201 | |
Dr. Briana Santaniello, PHARM.D., MBA Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 333 South St, Shrewsbury, MA 01545 Phone: 413-265-7252 | |
Mrs. Giovanna Maria Witowski, RPH, CDM Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 36 Blackthorn Rd, Shrewsbury, MA 01545 Phone: 508-845-9690 | |
Faten Hammoud, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16 Myriah Rd, Shrewsbury, MA 01545 Phone: 508-797-5516 | |
Alexis Williams, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 720 Boston Tpke, Shrewsbury, MA 01545 Phone: 508-845-6009 | |
Stephanie Tran, PHARM.D. Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 333 South St, Shrewsbury, MA 01545 Phone: 774-455-3320 | |
Jennifer Rose Trodella, Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 197 Boston Tpke, Shrewsbury, MA 01545 Phone: 508-752-0439 |